Current Report Filing (8-k)
October 13 2015 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 13, 2015 (October 6, 2015)
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-51820 |
|
77-0567768 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
Alexza Pharmaceuticals, Inc.
2091 Stierlin Court
Mountain View, California |
|
94043 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 5 Corporate Governance and Management
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(c) On October 6, 2015, the board of directors of Alexza Pharmaceuticals, Inc., a Delaware corporation, or the Company, appointed
Thomas B. King, the Companys president and chief executive officer, as the Companys principal financial officer and principal accounting officer, effective upon the resignation Mark K. Oki, the Companys current principal financial
officer and principal accounting officer, on October 16, 2015. Mr. King has served as the Companys president, chief executive officer and a member of the Companys board of directors since June 2003. Mr. King will not
receive any additional compensation in the 2015 fiscal year as a result of being appointed as the Companys principal financial offer and principal accounting officer.
The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K regarding Mr. King, as previously reported in the
Companys Schedule 14A, as filed with the Securities Exchange Commission on April 30, 2015, is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
ALEXZA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
Date: October 13, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Thomas B. King |
|
|
|
|
|
|
Thomas B. King President and Chief Executive
Officer |
|
|